JPH04164098A - Chemically modified granulocyte colony stimulating factor derivative - Google Patents

Chemically modified granulocyte colony stimulating factor derivative

Info

Publication number
JPH04164098A
JPH04164098A JP41895390A JP41895390A JPH04164098A JP H04164098 A JPH04164098 A JP H04164098A JP 41895390 A JP41895390 A JP 41895390A JP 41895390 A JP41895390 A JP 41895390A JP H04164098 A JPH04164098 A JP H04164098A
Authority
JP
Grant status
Application
Patent type
Prior art keywords
modified
glycol
amino
cys
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP41895390A
Inventor
Masatoshi Ishikawa
Shigeru Matsuki
Yuji Okada
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Abstract

PURPOSE: To obtain the chemically modified subject protein with extended blood retention time and long-lasting pharmacological activity, by linking polyeth ylene glycol to a human G-CSF polypeptide derivative wherein Cys at the 17-po sition is substituted by other amino acids.
CONSTITUTION: A polypeptide having the amino acid sequence of the formula (Xaa is an amino acid residue except Cys; Met may further be bonded to the tip of the N-terminal) which has been produced by a transformant obtained by transforming a host such as E. coli, animal cell, etc., in gene recombinant technique and has been separated and purifed, is reacted with an activated polyethylene glycol, e.g. methoxypolyethylene glycol succinidimylsuccinate, thereby to obtain the objective chemically modified protein. Example of the amino acid except Cys is preferably Ala and it is preferred to use polyethylene glycol with a molecular weight of 4,000-20,000. The resultant modified product is improved in its thertmostability and the yield in the modification is good.
COPYRIGHT: (C)1992,JPO
JP41895390A 1990-03-07 1990-12-14 Chemically modified granulocyte colony stimulating factor derivative Pending JPH04164098A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP5629190 1990-03-07
JP41895390A JPH04164098A (en) 1990-03-07 1990-12-14 Chemically modified granulocyte colony stimulating factor derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP41895390A JPH04164098A (en) 1990-03-07 1990-12-14 Chemically modified granulocyte colony stimulating factor derivative

Publications (1)

Publication Number Publication Date
JPH04164098A true true JPH04164098A (en) 1992-06-09

Family

ID=26397241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP41895390A Pending JPH04164098A (en) 1990-03-07 1990-12-14 Chemically modified granulocyte colony stimulating factor derivative

Country Status (1)

Country Link
JP (1) JPH04164098A (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010089A1 (en) * 1994-09-29 1996-04-04 Ajinomoto Co., Inc. Modification of peptide and protein
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
JP2004508044A (en) * 2000-09-08 2004-03-18 マサチューセッツ インスティテュート オブ テクノロジーMassachusetts Institute of Technology G-csf analog compositions and methods
US7947655B2 (en) 1999-01-14 2011-05-24 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7959909B2 (en) 1997-07-14 2011-06-14 Bolder Biotechnology, Inc. Cysteine variants of interferon gamma
US7994124B2 (en) 1997-07-14 2011-08-09 Bolder Biotechnology, Inc. Methods of use of G-CSF cysteine muteins
US8133480B2 (en) 1997-07-14 2012-03-13 Bolder Biotechnology, Inc. Cysteine variants of interleukin-11
US8148500B2 (en) 1997-07-14 2012-04-03 Bolder Biotechnology, Inc. Method of preparing cysteine mutants of human recombinant GM-CSF
US8524655B2 (en) 2004-11-05 2013-09-03 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
US8957023B2 (en) 1999-01-14 2015-02-17 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
EP0785276A1 (en) * 1994-09-29 1997-07-23 Ajinomoto Co., Inc. Modification of peptide and protein
WO1996010089A1 (en) * 1994-09-29 1996-04-04 Ajinomoto Co., Inc. Modification of peptide and protein
US8618256B2 (en) 1997-07-14 2013-12-31 Bolder Biotechnology Cysteine variants of interferon gamma
US8859497B2 (en) 1997-07-14 2014-10-14 Bolder Biotechnology, Inc. Method of treatment using cysteine mutants of beta interferon
US8748392B2 (en) 1997-07-14 2014-06-10 Bolder Biotechnology Inc. Methods of treatment using cysteine variants of interleukin-11
US7959909B2 (en) 1997-07-14 2011-06-14 Bolder Biotechnology, Inc. Cysteine variants of interferon gamma
US7964184B2 (en) 1997-07-14 2011-06-21 Bolder Biotechnology, Inc. Cysteine variants of interferon-gamma
US7994124B2 (en) 1997-07-14 2011-08-09 Bolder Biotechnology, Inc. Methods of use of G-CSF cysteine muteins
US8133480B2 (en) 1997-07-14 2012-03-13 Bolder Biotechnology, Inc. Cysteine variants of interleukin-11
US8148500B2 (en) 1997-07-14 2012-04-03 Bolder Biotechnology, Inc. Method of preparing cysteine mutants of human recombinant GM-CSF
US9637530B2 (en) 1997-07-14 2017-05-02 Bolder Biotechnology, Inc. Methods of preparing cysteine variants of human recombinant IL-11
US7947655B2 (en) 1999-01-14 2011-05-24 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US8957023B2 (en) 1999-01-14 2015-02-17 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
JP2004508044A (en) * 2000-09-08 2004-03-18 マサチューセッツ インスティテュート オブ テクノロジーMassachusetts Institute of Technology G-csf analog compositions and methods
JP4799803B2 (en) * 2000-09-08 2011-10-26 マサチューセッツ インスティテュート オブ テクノロジー G-csf analog compositions and methods
US8524655B2 (en) 2004-11-05 2013-09-03 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders

Similar Documents

Publication Publication Date Title
Nachman et al. Leucosulfakinin, a sulfated insect neuropeptide with homology to gastrin and cholecystokinin
US5824778A (en) Chemically-modified G-CSF
US5981709A (en) α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
Thomas et al. Fibroblast growth factors: broad spectrum mitogens with potent angiogenic activity
US4879226A (en) Novel human physiologically active polypeptide
Atoda et al. The primary structure of coagulation factor IX/factor X-binding protein isolated from the venom of Trimeresurus flavoviridis. Homology with asialoglycoprotein receptors, proteoglycan core protein, tetranectin, and lymphocyte Fc epsilon receptor for immunoglobulin E.
Nachman et al. Leucosulfakinin-II, a blocked sulfated insect neuropeptide with homology to cholecystokinin and gastrin
Kokryakov et al. Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins
Liang et al. Properties and amino acid sequence of huwentoxin-I, a neurotoxin purified from the venom of the Chinese bird spider Selenocosmia huwena
Hillyard et al. A molluskivorous Conus toxin: conserved frameworks in conotoxins
US5202415A (en) Insulin precursors
She et al. A novel lectin with potent immunomodulatory activity isolated from both fruiting bodies and cultured mycelia of the edible mushroomVolvariella volvacea
EP0077670A2 (en) Human immune interferon
EP0215126A1 (en) Human granulocyte colony stimulating factor
EP0442724A2 (en) Modified hIL-6
US6143866A (en) Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US5736363A (en) IGF-II analogues
Cha et al. Development of bioadhesives from marine mussels
US4316890A (en) Peptides and processes for the manufacture thereof
US5120535A (en) Oncostatin M and novel compositions having anti-neoplastic activity
US5256769A (en) Mutual separation of proteins
US5585353A (en) Antibiotic peptides containing D-amino acids
WO1986007595A1 (en) Fibroblast growth factor
Lowbridge et al. Synthesis and some pharmacological properties of [4-threonine, 7-glycine] oxytocin,[1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine] oxytocin (hydroxy [Thr4, Gly7] oxytocin), and [7-Glycine] oxytocin, peptides with high oxytocic-antidiuretic selectivity
Zhang et al. Cloning, characterization and expression analysis of interleukin-10 from the zebrafish (Danio rerion)